The Motley Fool

2 FTSE 100 dividend stocks I’d buy and hold for the next 10 years

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images.

With the FTSE 100 having a dividend yield of around 4.3%, there are numerous income investing opportunities available to investors at the present time.

In the long run, many of those companies could offer improving financial performance that boosts their share prices. And, since their valuations continue to be low in many cases, now could be the right time to buy them.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Here are two prime examples of dividend stocks that could outperform the FTSE 100 in the next decade.


Healthcare companies such as GSK (LSE: GSK) could experience strong earnings growth over the next 10 years. Demand for a range of healthcare services and drugs is likely to increase as the world’s population grows in size and also continues to see its average age rise.

GSK’s recent updates have shown that it is making progress in implementing its current strategy. This includes a joint venture within its consumer health brands portfolio, as well as M&A activity within its pharma sector. These changes could catalyse its financial performance and increase its appeal among investors.

The company’s dividend has been frozen on a per share basis over recent years. This has been a positive move in terms of the overall financial health of the business, since it now means that dividends are covered 1.5 times by net profit. There may now be scope for shareholder payouts to increase at a brisk pace, while a dividend yield of 4.5% is competitive compared to other FTSE 100 stocks.

With GSK trading on a price-to-earnings (P/E) ratio of 15, it seems to offer good value for money given its long-term prospects. As such, now could be the right time to buy a slice of it.


Another FTSE 100 share that could be worth buying and holding for the next decade is Berkeley (LSE: BKG). The prime housebuilder, which focuses on the London market, has experienced a challenging set of trading conditions in recent years.

Planning difficulties and lower demand following the EU referendum have contributed to weaker levels of profitability. However, the company is placed favourably to benefit from an improvement in the London housing market, where it has a large market share compared to many of its sector peers.

Encouragingly, Berkeley has a strong balance sheet and an ability to focus on long-term projects. This strategy is performing relatively well according to its recent updates, with the company on track to meet its medium-term financial guidance.

With the stock forecast to pay a dividend yield of 3.5% in the current year and 4.1% next year, it continues to offer sound income opportunities. And, with the London property market having the potential to gain ground as political risk subsides, now could be the right time to buy a slice of the stock and hold it for the long run.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Peter Stephens owns shares of Berkeley Group Holdings and GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.